drugset / Trial / NCT00334412

COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis

NCT00334412

Phase 4 Completed 30 enrolled Gilead Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

Combination therapy of caspofungin and amphotericin B could be a useful treatment option in invasive fungal disease, but before it can be routinely recommended; carefully controlled and well-designed randomized clinical trials are needed.

Timeline

Start
2004-03
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown Intravenous
Subject Caspofungin Other / unclassified Intravenous